Celgene Corp (CELG):企業の財務・戦略的SWOT分析

◆英語タイトル:Celgene Corp (CELG) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15301
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:64
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Celgene Corp (CELG) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Celgene Corp (Celgene) is an integrated global biopharmaceutical company that carries out the research, development, manufacture and marketing of novel therapies to treat cancer and immune-inflammatory related diseases through gene and protein regulation. Its product portfolio includes Vidaza (azacitidine) for the treatment of myelodysplastic syndromes (MDS); Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide) for the treatment of multiple myeloma; Abraxane (paclitaxel albumin-bound particles for injectable suspension) for various types of cancers; Otezla (apremilast) for psoriatic arthritis; and Istodax (romidepsin) for cutaneous T-cell lymphoma (CTCL) and Peripheral T-cell lymphoma (PTCL). The company also has several products in various stages of development for the treatment of hematological and solid tumor cancers. It has manufacturing facilities in Boudry and Zofingen in Switzerland; and Arizona, the US. The company sells its products through own sales organizations and distributors in the Americas, Europe, the Middle-East and Asia-Pacific. Celgene is headquartered in Summit, New Jersey, the US.

Celgene Corp Key Recent Developments

Mar 11,2019 Celgene files for EU approval of ozanimod in relapsingremitting MS with US resubmission on track httpswww.firstwordpharma.comnode1628754Â $CELG
Mar 11,2019 Celgene Submits Application to EMA for Ozanimod for the Treatment of RelapsingRemitting Multiple Sclerosis
Mar 04,2019 Adagene announces a platform evaluation of the dynamic precision library with Celgene
Mar 01,2019 BMS faces shareholder opposition to $74bn Celgene acquisition

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Celgene Corp – Key Facts
Celgene Corp – Key Employees
Celgene Corp – Key Employee Biographies
Celgene Corp – Major Products and Services
Celgene Corp – History
Celgene Corp – Company Statement
Celgene Corp – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Celgene Corp – Business Description
Product Category: Abraxane
Overview
Performance
Product Category: Azacitidine for injection
Overview
Performance
Product Category: Idhifa
Overview
Performance
Product Category: Istodax
Overview
Performance
Product Category: Otezla
Overview
Performance
Product Category: Pomalyst/Imnovid
Overview
Performance
Product Category: Revlimid
Overview
Performance
Product Category: Thalomid
Overview
Performance
Product Category: Vidaza
Overview
Performance
Product Category: Other Revenue
Performance
Product Category: Product Revenue
Performance
Geographical Segment: International
Performance
Geographical Segment: The US
Performance
R&D Overview
Celgene Corp – SWOT Analysis
SWOT Analysis – Overview
Celgene Corp – Strengths
Celgene Corp – Weaknesses
Celgene Corp – Opportunities
Celgene Corp – Threats
Celgene Corp – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Celgene Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 11, 2019: Celgene files for EU approval of ozanimod in relapsingremitting MS with US resubmission on track httpswww.firstwordpharma.comnode1628754Â $CELG
Mar 11, 2019: Celgene Submits Application to EMA for Ozanimod for the Treatment of RelapsingRemitting Multiple Sclerosis
Mar 04, 2019: Adagene announces a platform evaluation of the dynamic precision library with Celgene
Mar 01, 2019: BMS faces shareholder opposition to $74bn Celgene acquisition
Feb 26, 2019: Celgene Corporation Announces Key Regulatory Updates for REVLIMIDÂ in Lymphoma and Luspatercept in MDS and BetaThalassemia
Feb 25, 2019: Gainey McKenna & Egleston Announces that It Filed a Class Action Lawsuit Against Celgene Corporation (CELG) And Its Directors
Feb 20, 2019: Bristol-Myers Squibb Provides Update on Pending Transaction with Celgene
Feb 05, 2019: Lyfebulb and Celgene announce call for innovation challenge applications to address unmet needs in multiple sclerosis
Feb 05, 2019: Wellcome commits £10 million to DNDi to develop new generation of oral drugs to treat leishmaniasis
Jan 31, 2019: Celgene reports fourth quarter and full year 2018 operating and financial results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Celgene Corp, Key Facts
Celgene Corp, Key Employees
Celgene Corp, Key Employee Biographies
Celgene Corp, Major Products and Services
Celgene Corp, History
Celgene Corp, Other Locations
Celgene Corp, Subsidiaries
Celgene Corp, Key Competitors
Celgene Corp, Ratios based on current share price
Celgene Corp, Annual Ratios
Celgene Corp, Annual Ratios (Cont...1)
Celgene Corp, Annual Ratios (Cont...2)
Celgene Corp, Interim Ratios
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Celgene Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Celgene Corp, Performance Chart (2014 - 2018)
Celgene Corp, Ratio Charts
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Celgene Corp, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Celgene Corp (CELG):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lixil Group Corporation (5938):企業の財務・戦略的SWOT分析
    Lixil Group Corporation (5938) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Water Intelligence PLC (WATR):企業の財務・戦略的SWOT分析
    Summary Water Intelligence plc (Water Intelligence) formerly Qonnectis Plc, is a clean technology company that offers environmental and technology services. The company offers services such as finding, detecting, and remediating water leaks services. It monitors and protects water infrastructure and …
  • Cytodyn Inc (CYDY):企業の財務・戦略的SWOT分析
    Summary Cytodyn Inc (Cytodyn), formerly RexRay Corp, is a biotechnology company. It develops and commercializes monoclonal antibodies for the treatment of Human Immunodeficiency Virus (HIV) infections. It is investigating Leronlimab (PRO 140), a fully humanized IgG4 monoclonal antibody directed agai …
  • Doosan Corporation:企業の戦略・SWOT・財務情報
    Doosan Corporation - Strategy, SWOT and Corporate Finance Report Summary Doosan Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • The Hour Glass Ltd (AGS):企業の財務・戦略的SWOT分析
    The Hour Glass Ltd (AGS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • United Networks Ltd (UNL):企業の財務・戦略的SWOT分析
    United Networks Ltd (UNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Pt Bumi Resources Tbk:企業の戦略・SWOT・財務分析
    Pt Bumi Resources Tbk - Strategy, SWOT and Corporate Finance Report Summary Pt Bumi Resources Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Gentera SAB de CV (GENTERA):企業の財務・戦略的SWOT分析
    Gentera SAB de CV (GENTERA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • U.S. Army Institute of Surgical Research:製薬・医療:M&Aディール及び事業提携情報
    Summary U.S. Army Institute of Surgical Research (USAISR), a subsidiary of U.S. Army, is a medical research center that offers solutions for burn, trauma, and combat casualty care from time of injury to rehabilitation. The center conducts research in the areas of dental and trauma research detachmen …
  • Proteome Sciences Plc (PRM):企業の製品パイプライン分析
    Summary Proteome Sciences Plc (Proteome Sciences) is a life sciences company that delivers content for personalized medicine through biomarkers, reagents and services. Its proteomics services include drug development, biomarker discovery, quality management and provision of data insights. The compan …
  • Bial – Portela & Ca SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Bial - Portela & Ca SA (BIAL) is a pharmaceutical company that discovers, develops and provides drugs for neurosciences and cardiovascular therapeutic areas. The company offers products such as anti-inflammatories, anti-diabetics, cardiovascular, anti-asthmatics, antibiotics, antidepressants …
  • Waste Management, Inc. (WM):電力:M&Aディール及び事業提携情報
    Summary Waste Management, Inc. (WM) is a provider of waste management environmental services. The company has a presence in waste management vertical from collection, solid and hazardous waste landfills management, transfer, recycling and resource recovery, to disposal. It also develops, operates, a …
  • Magellan Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Magellan Diagnostics Inc (Magellan Diagnostics), formerly ESA Inc, a subsidiary of Meridian Bioscience Inc, is a medical device company that provides point-of-care systems, clinical laboratory instruments, and analytical laboratory services. The company’s products include LeadCare II, LeadCa …
  • Alcami Corp:企業の戦略的SWOT分析
    Alcami Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Investec Private Bank (South Africa):企業の戦略・SWOT・財務情報
    Investec Private Bank (South Africa) - Strategy, SWOT and Corporate Finance Report Summary Investec Private Bank (South Africa) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Channel Four Telivision Corp:企業の戦略的SWOT分析
    Channel Four Telivision Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • TransForce Inc.:企業のM&A・事業提携・投資動向
    TransForce Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's TransForce Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Swagelok Company:企業の戦略・SWOT・財務情報
    Swagelok Company - Strategy, SWOT and Corporate Finance Report Summary Swagelok Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Deutsche Telekom AG:企業の戦略・SWOT・財務情報
    Deutsche Telekom AG - Strategy, SWOT and Corporate Finance Report Summary Deutsche Telekom AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Prism Cement Ltd:企業の戦略・SWOT・財務情報
    Prism Cement Ltd - Strategy, SWOT and Corporate Finance Report Summary Prism Cement Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆